Gaurav Mishra | Intellepedia

Patent (Amendment) Rules 2024 come into effect, significant changes introduced.

The Patent (Amendment) Rules 2024 bring notable procedural changes to the Indian patent system, including shorter timelines, new forms, and updated requirements. These amendments aim to simplify processes and enhance compliance for patent applicants and patentees.

Kudos Pharma v. Natco Pharma: A case on patent claims, coverage, validity and infringement.

The Delhi High Court’s decision in Kudos Pharma v. Natco Pharma reviews crucial aspects of patent law, including credible challenge and the distinction between patent coverage and disclosure. The Court granted an interim injunction to Kudos Pharma, reinforcing core principles of Indian patent jurisprudence.

Objections regarding insufficiency of disclosure in patent applications must be clear and unambiguous

The Delhi High Court has reiterated that objections on insufficiency of disclosure in patent applications must be clear and precise. Procedural lapses by the Indian patent office can undermine the fairness of the patent examination process.

PSITA is not omniscient, says Madras High Court. Overturns refusal order in favour of Microsoft.

The Madras High Court has overturned the refusal of Microsoft’s patent application, clarifying the correct approach to assessing inventive step and the PSITA standard under Indian law. The decision highlights the need for a nuanced analysis of prior art and patent claims.

Missed filing a request for examination? court says, condonable under exceptional circumstances.

The Madras High Court held that delays in filing a request for examination can be condoned under exceptional circumstances, particularly when caused by agent errors. This case highlights both the strict nature of Indian patent timelines and the judiciary’s role in allowing limited flexibility.

After Natco, Bajaj Healthcare files compulsory license against Eli Lilly; EPO Enlarged Board of Appeal issues decision on ‘double patenting’ and more

Bajaj Healthcare has applied for a compulsory license against Eli Lilly for Baricitinib, citing affordability concerns. The post also covers the EPO’s decision on double patenting, updates from the IP5 meeting on AI patents, and new initiatives by WHO, WTO, and WIPO.

Free Masterclass on IP; Nokia and Daimler settle SEP patent dispute; EU submits alternative proposal to WTO against IP waiver and more

This week’s patent news features a free masterclass on patent filing, Nokia and Daimler’s settlement of a SEP dispute, and the EU’s alternative proposal to the WTO on IP waivers. Also covered are updates on the USPTO’s move to structured text filing for patent applications.

Drastic decrease in patent publications and grants this week

This week’s Indian patent statistics reveal a notable decline in patent publications and grants compared to the previous week. The report offers a comprehensive breakdown by city and category, compiled by BananaIP Counsels.

Differentiating Patents and Industrial Designs

The article analyses the differences between patents and industrial designs as forms of intellectual property in India. It examines legal definitions, protection criteria, statutory frameworks, and clarifies common misconceptions, providing a structured comparison for better understanding.

Indian Patent Office working at Lightning Speeds

Recent developments at the Indian Patent Office highlight a remarkable increase in the speed of patent processing and grants. Policy reforms and increased staffing have led to faster publication and examination, offering significant benefits to applicants.